Ingredients & DescriptionBest Artemisinin contains high quality Artemisinin or Ching-hao-su, an extract from the traditional Chinese herb Artemisia annua (sweet wormwood) or Ching-hao. Sweet wormwood leaves have been consumed over several centuries for promoting general health. The extract Artemisinin has been used for several decades.
Best Artemisinin is encapsulated in the U.S. with the artemisinin by Holley Pharmaceuticals, a worldwide leader in high quality artemisinin research and production for 30 years, and is extracted from plants grown and harvested in accordance with GAP (Good Agricultural Practice) standards. The extract itself is manufactured to the highest pharmaceutical-grade quality specifications in a certified GMP (Good Manufacturing Practice) facility, ensuring the highest potency.
Suggested Use: Take 1 to 2 capsules, once or twice daily on an empty stomach. Sensitive individuals may take with food.
|Supplement Facts |
Serving Size: 1 vegetable capsule
|Artemisinin (from sweet wormwood (Artemisia annua))||100 mg|
Daily Value not established.
Other Ingredients: Vegetable capsule, cellulose, magnesium stearate (vegetable source). Contains nothing other than listed ingredients.
Following is a historical description from the Natural Standard database (www.naturalstandard.com)- the authority on integrative medicine.
Although Artemisia annua was used as an antipyretic 2,000 years ago by Chinese doctors, it fell out of favor and was forgotten until the Chinese Handbook of Prescriptions for Emergency Treatments (340 AD) rediscovered it in 1970. The handbook contained an Artemisia annua decoction for treating fevers, but not necessarily malaria. Interest in the herb was revived, and the constituent artemisinin was isolated from the plant in 1971 (15; 50; 51). Further research identified dihydroartemisinin, artemether, and artesunate, which, along with artemisinin, are being currently used to treat drug-resistant and non-drug resistant malaria (14; 15; 16). According to one review, the demand for artemisinin combination therapies is very high with approximately 120 million adult treatment courses used for just one artemisinin combination therapy, artemether-lumifantrine. Artemether-lumifantrine constitutes about 70% of all current clinically-used artemisinin combination therapies (41). Approximately 114 tons of artemisinin is required to fill this number of courses. Although artemisinin is found in Artemisia annua, Artemisia apiacea, and Artemisia lancea, it has a relatively low yield; there is 0.01-0.8% of artemisinin in Artemisia annua, which may seriously limit the drug's commercialization (26; 47). The high demand for artemisinin and low concentration in the plants has placed a substantial stress on plant supplies worldwide (41).